We designed a potent and selective small-molecule RORγt agonist (8-074) that shows robust antitumor efficacy in syngeneic tumor models and improves the efficacy of anti‐PD‐1 in a murine lung cancer model. This evidence concerns the gene PDCD1 and lung carcinoma.